LGVN
LongeveronLGVN
LGVN
About: Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
Employees: 25
0
Funds holding %
of 7,323 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0.13% more ownership
Funds ownership: 3.65% [Q4 2024] → 3.78% (+0.13%) [Q1 2025]
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
6% less capital invested
Capital invested by funds: $844K [Q4 2024] → $791K (-$53.8K) [Q1 2025]
13% less funds holding
Funds holding: 23 [Q4 2024] → 20 (-3) [Q1 2025]
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Research analyst outlook
We haven’t received any recent analyst ratings for LGVN.
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease
Longeveron has licensed issued US Patent 12,168,028 B2 , entitled “Methods for obtaining cardiomyogenic precursor cells” from the University of Miami New patent protects a method to derive GHRH-Receptor+ cardiomyogenic cells from pluripotent stem cells (PSCs) New technology substantially advances Longeveron's repertoire of stem cell therapy technologies Opportunity to expand pipeline in cardiovascular, rare and pediatric disease areas MIAMI, July 21, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric, and chronic aging-related conditions, today announced that it has licensed an issued US patent (12,168,028 B2) for a stem cell technology from the University of Miami. The composition of matter patent protects unique induced pluripotent derived cardiomyogenic cells that have widespread therapeutic indications for heart diseases.
Neutral
GlobeNewsWire
3 weeks ago
Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)
FDA approves Longeveron's Investigational New Drug (IND) application for stem cell therapy as a potential treatment for pediatric dilated cardiomyopathy.
Neutral
GlobeNewsWire
1 month ago
Longeveron® Appoints Than Powell as Chief Business Officer
Mr. Powell to oversee Longeveron's partnering and international strategy efforts MIAMI, June 26, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Than Powell as Chief Business Officer, effective July 7, 2025. In this role, he will lead the Company's overall business strategy, Alzheimer's disease program partnering efforts, and international strategy for the hypoplastic left heart syndrome (HLHS) program.
Neutral
GlobeNewsWire
1 month ago
Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Longeveron® completes enrollment of pivotal Phase 2b clinical trial evaluating laromestrocel as a treatment for Hypoplastic Left Heart Syndrome (HLHS).
Neutral
GlobeNewsWire
1 month ago
Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
MIAMI, June 09, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that Wa'el Hashad, CEO, will present at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference, taking place June 16-17, 2025.
Neutral
GlobeNewsWire
2 months ago
Longeveron® to Attend BIO International Convention 2025
Longeveron to host Alzheimer's disease program partnering meetings at BIO 2025 conference June 16-19. Positive Phase 2a data published in Nature Medicine.
Neutral
GlobeNewsWire
2 months ago
Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient
Longeveron selected as a Top 40 Semifinalist based on the feasibility of its stem cell therapy Stem cell therapy laromestorcel being evaluated as potential treatment for Alzheimer's disease and HLHS, a rare pediatric disease and orphan-designated indication MIAMI, May 12, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has been selected as a Semi-Finalist Team and one of the Top 40 Teams receiving a $250,000 Milestone 1 Award in the XPRIZE Healthspan competition. “We're proud to be a Semifinalist team of XPRIZE Healthspan, a 7-year, $101 million global competition that aims to revolutionize the way we approach human aging,” said Wa'el Hashad , Chief Executive Officer of Longeveron.
Neutral
Seeking Alpha
2 months ago
Longeveron Inc. (LGVN) Q1 2025 Earnings Call Transcript
Longeveron Inc. (NASDAQ:LGVN ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Derek Cole - Investor Relations-Advisory Solutions Joshua Hare - Co-Founder, Chief Science Officer & Chairman of the Board Wa'el Hashad - Chief Executive Officer Nataliya Agafonova - Chief Medical Officer Devin Blass - Chief Technology Officer Lisa Locklear - Chief Financial Officer Conference Call Participants Boobalan Pachaiyappan - ROTH Capital Ram Selvaraju - H.C. Wainwright Michael Okunewitch - Maxim Group Operator Greetings and welcome to the Longeveron First Quarter 2025 Earnings Call.
Neutral
GlobeNewsWire
2 months ago
Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update
Longeveron announces Q1 2025 financial results & provides business update. Pivotal Phase 2 clinical trial achieves 95% enrollment. Expected full enroll Q2.
Neutral
GlobeNewsWire
2 months ago
Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
Longeveron (LGVN) will report Q1 2025 financial results and provide a business update on Thursday, May 8, 2025 after the U.S. financial markets close.
Charts implemented using Lightweight Charts™